Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.

Sato T, Suzuki Y, Mori T, Maeda M, Abe M, Hino O, Takahashi K.

Cancer Med. 2014 Oct;3(5):1377-84. doi: 10.1002/cam4.297. Epub 2014 Jul 10.

2.

Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.

Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M, Izumi H, Masuda K, Hirabayashi M, Moroboshi T, Yoshiyama T, Ishida A, Natori Y, Inoue A, Kobayashi M, Sakao Y, Miyamoto H, Takahashi K, Hino O.

Clin Cancer Res. 2008 Mar 1;14(5):1431-7. doi: 10.1158/1078-0432.CCR-07-1613.

3.

Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma.

Hagiwara Y, Hamada Y, Kuwahara M, Maeda M, Segawa T, Ishikawa K, Hino O.

Cancer Sci. 2008 Apr;99(4):666-70. doi: 10.1111/j.1349-7006.2008.00731.x. Epub 2008 Feb 24.

4.

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.

Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ, Nowak AK, Robinson BW.

Thorax. 2014 Oct;69(10):895-902. doi: 10.1136/thoraxjnl-2014-205205. Epub 2014 Jul 18.

5.

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.

Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodríguez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ, van Meerbeeck JP.

J Clin Oncol. 2012 May 1;30(13):1541-9. doi: 10.1200/JCO.2011.39.6671. Epub 2012 Mar 12. Review.

6.

Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.

Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M, Takahashi K, Masuda K, Sakao Y, Hino O.

Cancer Sci. 2006 Sep;97(9):928-32. Epub 2006 Jun 7.

7.

Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.

Mundt F, Nilsonne G, Arslan S, Csürös K, Hillerdal G, Yildirim H, Metintas M, Dobra K, Hjerpe A.

PLoS One. 2013 Aug 21;8(8):e72030. doi: 10.1371/journal.pone.0072030. eCollection 2013.

8.

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.

Pantazopoulos I, Boura P, Xanthos T, Syrigos K.

Eur Respir J. 2013 Mar;41(3):706-15. doi: 10.1183/09031936.00226111. Epub 2012 Jul 26. Review.

9.

Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.

Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J.

J Thorac Oncol. 2013 Jul;8(7):947-51. doi: 10.1097/JTO.0b013e31828f696b.

10.

Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.

Creaney J, Dick IM, Segal A, Musk AW, Robinson BW.

Lung Cancer. 2013 Dec;82(3):491-8. doi: 10.1016/j.lungcan.2013.09.016. Epub 2013 Oct 9.

PMID:
24161718
11.

Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.

Maeda M, Hino O.

Pathol Int. 2006 Nov;56(11):649-54. Review.

PMID:
17040286
12.

Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.

Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T.

Clin Chem Lab Med. 2011 Oct;49(10):1721-6. doi: 10.1515/CCLM.2011.242. Epub 2011 Jun 22.

PMID:
21692685
13.

Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.

Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P.

Clin Cancer Res. 2007 May 15;13(10):2928-35.

14.

Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.

Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S.

Cancer Invest. 2013 Jan;31(1):43-50. doi: 10.3109/07357907.2012.749265. Epub 2012 Dec 18.

PMID:
23249166
15.

Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.

Ferro P, Canessa PA, Battolla E, Dessanti P, Franceschini MC, Chiaffi L, Morabito A, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2013 Jun;33(6):2707-13.

PMID:
23749930
16.

Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.

Bayram M, Dongel I, Akbaş A, Benli I, Akkoyunlu ME, Bakan ND.

Lung. 2014 Feb;192(1):197-203. doi: 10.1007/s00408-013-9526-9. Epub 2013 Oct 30.

PMID:
24170217
17.

Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?

Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW.

Lung Cancer. 2011 Oct;74(1):55-60. doi: 10.1016/j.lungcan.2011.02.007. Epub 2011 Mar 12.

PMID:
21397972
18.

Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.

Franceschini MC, Ferro P, Canessa PA, Battolla E, Dessanti P, Valentino A, Casolari L, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2014 Dec;34(12):7425-9.

PMID:
25503183
19.

Sensitivity of urinary mesothelin in patients with malignant mesothelioma.

Creaney J, Musk AW, Robinson BW.

J Thorac Oncol. 2010 Sep;5(9):1461-6.

20.

MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.

Segawa T, Hagiwara Y, Ishikawa K, Aoki N, Maeda M, Shiomi K, Hino O.

Biochem Biophys Res Commun. 2008 May 9;369(3):915-8. doi: 10.1016/j.bbrc.2008.02.114. Epub 2008 Mar 5.

PMID:
18328258

Supplemental Content

Support Center